Abstract: Today, the incidence of type 2 diabetes mellitus is increasing rapidly on global. This disease is shown with many complications that significantly affect public health. One of them is kidney complications, which have a high incidence among diabetic patients in Vietnam (25.6-33.1%). Age, history of hypertension, and dyslipidemia are considered to be the main risk factors for diabetic nephropathy. Thus, early detection of these factors for kidney damage is significant for diagnosing, monitoring, treatment, and prognosis of diabetic patients. Our descriptive, cross-sectional study conducting on 120 diabetic patients at E Hospital has observed that blood cholesterol levels, HbA1c levels were independently related to eGFR decline below 60 mL/min/1.73m2. From those data, an equation to predict the risk of diabetic kidney disease was estimated as p =  with k = Keyword: Type 2 diabetes, Diabetic nephropathy, Risk factor Today, the incidence of type 2 diabetes mellitus is increasing rapidly on global. This disease is shown with many complications that significantly affect public health. One of them is kidney complications, which have a high incidence among diabetic patients in Vietnam (25.6-33.1%). Age, history of hypertension, and dyslipidemia are considered to be the main risk factors for diabetic nephropathy. Thus, early detection of these factors for kidney damage is significant for diagnosing, monitoring, treatment, and prognosis of diabetic patients. Our descriptive, cross-sectional study conducting on 120 diabetic patients at E Hospital has observed that blood cholesterol levels, HbA1c levels were independently related to eGFR decline below 60 mL/min/1.73m2. From those data, an equation to predict the risk of diabetic kidney disease was estimated as p =  with k = Keyword Type 2 diabetes, Diabetic nephropathy, Risk factor. References [1] N. H. Cho, J. Kirigia, J. C. Mnanya, K. Ogurstova, L. Guraiguata, W. Rathmann, G. Roglic, N. Forouhi, R. Dajani, A. Esteghmati, E. Boyko, L. Hambleton, O. L. M. Neto, P. A. Montoya, S. Joshi, J. Chan, J. Shaw, T.A. Samuels, M. Pavkov, A. Reja, IDF Diabetes Atlas Eight Edition, International Diabete Federation, England, 2017.[2] N. T. Khue, Diabetes – General Endocrinology, Ho Chi Minh Publisher, Ho Chi Minh city, 2003 (in Vietnamese). [3] H. H. Kiem, Clinical Nephrology, Medical Publishing House, Hanoi, 2010 (in Vietnamese). [4] T. H. Quang, Practice Diabetes - Endocrine Disease, Medical Publishing House Hanoi, Hanoi, 2010 (in Vietnamese). [5] D. T. M. Hao, T. T. A. Thu, Diabetic Kidney Disease: Attention Problems, Vietnam Journal of Diabetes and Endocrinology, Vol. 38, 2020, pp. 12-17 (in Vietnamese), https://doi.org/10.47122/vjde.2020.38.2. [6] K. Tziomalos, A. Vasilios G, Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis, The Review of Diabetic Studies: RDS, Vol. 12, No. 1-2, 2015, pp. 110-118, https://doi.org/10.1900/RDS.2015.12.110.[7] American Diabetes Association, 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020, Journal Diabetes Care, Vol. 43, No. 1, 2020, pp. S14, https://doi.org/10.2337/dc20-S002.[8] A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, R. J. Hogg, R. D. Perrone, J. Lau, G. Eknoyan, National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Ann Intern Med, Vol. 139, 2003, pp. 137-147, https://doi.org/10.7326/0003-4819-139-2-200307150-00013.[9] D. S. Freedman, M. Horlick, G. S. Berenson, A Comparison of The Slaughter Skinfold-thickness Equations and BMI in Predicting Body Fatness and Cardiovascular Disease Risk Factor Levels in Children, The American Journal of Clinical Nutrition, Vol. 98, No. 6, 2013, pp. 1417-1424, https://doi.org/10.3945/ajcn.113.065961.[10] National Heart, Lung and Blood Institutes, National Cholesterol Education Program: ATP III Guidelines at-a-glance Quick Desk Reference, https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf, (accessed on: 5th April 2021).[11] K. Eckardt, B. Kasiske, D. Wheeler, K. Uhlig, D. Miskulin, A. Earley, S. Haynes, J. Lamont, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Definition and Classification of CKD, Kidney International Supplements, Vol. 3, 2013, pp. 5-14, https://doi.org/10.1038/kisup.2012.77.[12] I. H. Boer, M. L. Caramori, J. C. N. Chan, H. J. L. Heerspink, C. Hurst, K. Khunti, A. Liew, E. D. Michos, S. D. navaneethan, P. Rossing, W. A. Olowu, T. Sadusky, N. Tandon, K. R. Tuttle, C. Wanner, K. G. Wilkens, S. Zoungas, KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, Kidney international, Vol. 98, No. 4S, 2020, pp. S1-S115, http://dx.doi.org/10.1016/j.kint.2020.06.019.[13] B. T. T. Huong, N. T. Giang, Values of Cystatin C in Early Diagnosis of Renal Disease in Patients with Typ 2 Diabetes in Thai Nguyen National Hospital, Vietnam Medical Journal, Vol. 498, No. 2, 2021, pp. 13-17 (in Vietnamese).[14] L. X. Truong, N. D. Tai, T. Q. P. Linh, T. T. Nhung, The Prevalence of The Positive Microalbumin Urine in The Type 2 Diabetic Patients at District 2 Hospital, Y Hoc TP. Ho Chi Minh, Vol. 22, No. 2, 2018, pp. 139-143 (in Vietnamese).[15] S. Yi, S. Park, Y. Lee, H Park, B. Balkau, J. Yi, Association Between Fasting Glucose and All-cause Mortality According to Sex and Age: A Prospective Cohort Study, Scientific Reports, Vol. 7, No. 1, 2017, pp. 1-9, https://doi.org/10.1038/s41598-017-08498-6.[16] R. Gupta, M. Sharma, N. K. Goyal, P. S. Lodha, K. K. Sharma, Gender Differences in 7 Years Trends in Cholesterol Lipoproteins and Lipids in India: Insights From A Hospital Database, Indian Journal of Endocrinology Metabolism, Vol. 20, No. 2, 2016, pp. 211-8, https://doi.org/10.4103/2230-8210.176362.[17] X. Zhang, Z. Meng, X. Li, M. Liu, X. Ren, M. Zhu, Q. He, Q Zhang, K. Song, Q. Jia, C. Zhang, X Wang, X. Liu, The Association Between Total Bilirubin and Serum Triglyceride in Both Sexes in Chinese, Lipids In Health and Disease, Vol. 17, No. 1, 2017, pp. 1-8, https://doi.org/10.1186/s12944-018-0857-7.[18] S. Palazhy, V. Viswanathan, Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy, Diabetes Metabolism Journal, Vol. 41, No. 2, 2017, pp. 128-134, https://doi.org/ 10.4093/dmj.2017.41.2.128.[19] R. I. Papacocea, D. Timofte, M. Tanasescu, A. Balcangiu stroescu, D. G. Balan, A. Tulin, O. Stiru, I. A. Vacaroiu, A. Mihai, C. C. Popa, C. Cosconel, M. Enyedi, D. Miricescu, L. Raducu, D. Ionescu, Kidney Aging Process and The Management of The Elderly Patient with Renal Impairment, Experimental and Therapeutic Medicine, Vol. 21, 2021, pp. 266, https://doi.org/10.3892/etm.2021.9697.[20] R. D. Lindeman, Overview: Renal Physiology and Pathophysiology of Aging, Am J Kidney Dis, Vol. 16, 1990, pp. 275–282, https://doi.org/10.1016/s0272-6386(12)80002-3.[21] G. Zoppini, G. Targher, M. Chonchol, V. Ortalda, C. Negri, V. Stoicio, E. Bonora, Predictors of Estimated GFR Decline in Patients With Type 2 Diabetes and Preserved Kidney Function, Clinical Journal of the American Society of Nephrology, Vol. 7, No. 3, 2012, pp. 401-408, https://doi.org/10.2215/CJN.07650711.[22] R. Trevisan, A. R. Dodesini, G. Lepore, Lipids and Renal Disease, Journal of the American Society of Nephrology, Vol. 17, No. 2-4, 2006, pp. S145-S147. https://doi.org/10.1681/ASN.2005121320.[23] V. T. Samuel, G. I. Shulman, Mechanisms for Insulin Resistance: Common Threads and Missing Links, Cell, Vol. 148, No. 5, 2012, pp. 852-871, https://doi.org/10.1016/j.cell.2012.02.017.[24] W. Patricia, D. Gloria Michelle, F. Alessia, Systemic and Renal Lipids in Kidney Disease Development and Progression, American Journal of Physiology-Renal Physiology, Vol. 310, No. 6, 2016, pp. F433-F445, https://doi.org/ 10.1152/ajprenal.00375.2015.[25] F. M. Sacks, M. P. Hermans, P. Fioretto, P. Valensi, T. Davis, E. Horton, C. Wanner, K. A. Rubeaan, I. Barzon, L. Bishop, E. Bonora, P. Bunnag, L. Chuang, C. Deerochanawong, R. Goldenberg, B. Harshfiled, C. Hernandez, S. H. Botein, H. Itoh, W. Jia, Y. Jiang, T. Kadowaki, N. Laranjo, L. Leiter, T. Miwwa, M. Odawara, K. Ohashi, A. Ohno, C. Pan, J. Pan, J. P. Botet, Z. Reiner, C. M. Rotella, R. Simo, M. Tanaka, E. T. Reiner, D. T. Barima, G. Zoppini, V. J. Carey, Association between Plasma Triglycerides and High-density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–control Study In 13 Countries, Circulation. Vol. 129, No. 9, 2014, pp. 999-1008, https://doi.org/10.1161/CIRCULATIONAHA.113.002529.[26] Y. Wang, X. Qiu, L. Lv, C. Wang, Z. Ye, S. Li, Q. Liu, T. Lou, X. Liu, Correlation Between Serum Lipid Levels and Measured Glomerular Filtration Rate In Chinese Patients With Chronic Kidney Disease, PLoS One, Vol. 11, No. 10, 2016, pp. e0163767, https://doi.org/10.1371/journal.pone.0163767.[27] N. J. Radcliffe, J. Seah, M. Clarke, R. J. Maclsaac, G. Jerrums, E. I. Ekinci, Clinical Predictive Factors in Diabetic Kidney Disease Progression, Journal of Diabetes Investigation, Vol. 8, No. 1, 2017, pp. 6-18, https://doi.org/10.1111/jdi.12533.[28] D. D. Miao, E. C. Pan, Q. Zhang, Z. M. Sun, Y. Qin, M. Wu, Development and Validation of A Model for Predicting Diabetic Nephropathy in Chinese People, Biomedical and Environmental Sciences, Vol. 30, No. 2, 2017, pp. 106-112, https://doi.org/10.3967/bes2017.014.[29] R. G. Nelson, M. E. Grams, S. H. Ballew, Y. Sang, F. Azizi, S. J. Chadban, L. Chaker, S. C. Dunning, C. Fox, Y. Hirakawa, K. Iseki, J. Ix, T. H. Jafar, A. Kottgen, D. M. J. Naimark, T. Ohjubo, G. J. Prescott, C. M. Bebholz, C. Sabanayagam, T. Sairenchi, B. Schottker, Y. Shibagaki, M. Tonelli, L. Zhang, R. T. Gansevoort, K. Matsushita, M. Woodward, J. Coresh, V. Shalev, Development of Risk Prediction Equations For Incident Chronic Kidney Disease, Jama, Vol. 322, No. 21, 2019, pp. 2104-2114, https://doi.org/10.1001/jama.2019.17379.    

Abstract: This study presents a novel process to synthesize curcumin nanoparticles from fresh turmeric. An ultrasonic-assisted cajeput oil in water emulsion technique was used to synthesize nanocurcumin. The prepared nanocurcumin was spherical with an average size of 47 nm and size distribution of 5–80 nm. The synthesized nanocurcumin showed improved aqueous-phase solubility, and it was used as a reducing agent and stabilizer for biosynthesizing silver nanoparticles. Furthermore, the X-ray diffraction pattern of the silver nanoparticles showed four distinct diffraction peaks at 38.3°, 44.6°, 65.1°, and 78.1° corresponding to the lattice planes of face-centered cubic silver ((111), (200), (220), and (311)). Transmission electron microscopy analysis indicated the average size and maximum size distribution (80 %) of the silver nanoparticles were 10.9 nm and 5–15 nm, respectively. UV–visible spectroscopy measurement of samples indicated the localized surface plasmon resonance absorbance of an aqueous dispersion of silver nanoparticles at 406 nm. Zeta potential analysis revealed a negative charge with a magnitude of −27.2 mV, which indicated higher aqueous dispersion stability of the silver nanoparticles prepared from nanocurcumin. The nanoparticles showed antibacterial activity against Vibrio parahaemolyticus .

Abstract: Ở Việt Nam, những nghiên cứu về dược liệu Nở ngày đất (Gomphrena celosioides Mart.) vẫn còn ít ỏi và hạn chế. Vì vậy, nghiên cứu này được thực hiện nhằm khảo sát độc tính cấp và đánh giá tác động kháng viêm của cao đặc Nở ngày đất được chiết bằng dung môi nước. Đối tượng và phương pháp nghiên cứu: Để khảo sát độc tính cấp, nghiên cứu đã cho chuột uống cao dược liệu liều tối đa có thể qua đường uống và ghi nhận sự sống chết của chuột trong 72 giờ tiếp theo. Mô hình gây phù chân chuột bằng carragenan được thực hiện để đánh giá khả năng kháng viêm của Nở ngày đất. Sau khi gây viêm, chuột được cho uống cao và được theo dõi độ sưng phù bàn chân mỗi ngày trong suốt quá trình thử nghiệm. Kết quả - Thảo luận: Nghiên cứu xác định liều tối đa có thể qua kim (Dmax) không làm chết chuột thử nghiệm, không gây độc tính cấp đường uống trên chuộtlà 11,8g/kg. Ngoài ra, nghiên cứu cũng cho thấy cao nước Nở ngày đất thể hiện tác động kháng viêm ở liều 300mg/kg và 600mg/kg. Kết luận:Nở ngày đất không gây độc ở liều khảo sát và có tác động kháng viêm.Đây là cây thuốc có tiềm năng cao để điều trị các bệnh về viêm và cần đượcphân lập các nhóm chất có hoạt tính sinh học hoặc nghiên cứu thêm về các tác dụng dược lí khác.

Abstract: 〈 span 〉 Content addressable memory (CAM) and ternary content addressable memory (TCAM) are specialized high-speed memories for data searching. CAM and TCAM have many applications in network routing, packet forwarding and Internet data centers. These types of memories have drawbacks on power dissipation and area. As field-programmable gate array (FPGA) is recently being used for network acceleration applications, the demand to integrate TCAM and CAM on FPGA is increasing. Because most FPGAs do not support native TCAM and CAM hardware, methods of implementing algorithmic TCAM using FPGA resources have been proposed through recent years. Algorithmic TCAM on FPGA have the advantages of FPGAs low power consumption and high intergration scalability. This paper proposes a scaleable algorithmic TCAM design on FPGA. The design uses memory blocks to negate power dissipation issue and data collision to save area. The paper also presents a design of a 256 x 104-bit algorithmic TCAM on Intel FPGA Cyclone V, evaluates the performance and application ability of the design on large scale and in future developments. 〈 /span 〉

Abstract: This study is aimed at exploring undergraduate students’ abilities to recognize anxiety disorder and depression symptoms, and their literacy of mental first-aid supports for these problems. Using a mixed-method, cross-sectional design, data were collected from 724 undergraduate students in Hanoi. This used a questionnaire on literacy of anxiety disorder and depression, adapted from the Australian National Survey of Mental Health Literacy and Stigma. The prevalence of the respondents who could identify anxiety disorder and depression symptoms were 25.9% and 42.3%, respectively. Literacy of mental first-aid supports focused on: listening to the person in an understanding way, encouraging the person to be more active, seeking professional help, make appointment with the general doctor.

Abstract: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%] ; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%] ; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%] ; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%] ; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. Registration: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921.